Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 14,166 shares at $135.16 ($1.9M) on 2021-10-26, disclosed to the SEC on 2021-10-28.
Open-market sale of $1.9M NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.93 | 1,500 | $196K | 10.4% |
| 2 | $131.91 | 3,000 | $396K | 21.0% |
| 3 | $133.02 | 3,134 | $417K | 22.1% |
| 4 | $133.02 | 3,134 | $417K | 22.1% |
| 5 | $133.82 | 1,700 | $227K | 12.1% |
| 6 | $134.99 | 61 |
| $8K |
| 0.4% |
| 7 | $134.99 | 637 | $86K | 4.6% |
| 8 | $135.16 | 1,000 | $135K | 7.2% |
| Total | $132.91 avg | 14,166 | $1.9M | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |